Last reviewed · How we verify
A: EG-COVID
A: EG-COVID is a Small molecule drug developed by EyeGene Inc.. It is currently in Phase 1 development.
AEG-COVID is a small molecule intervention that has been studied in relation to COVID-19 infection, COVID-19 vaccine, COVID-19 pneumonia, SARS-CoV-2, and SARS-CoV-2 through various methods including blood draws, fingertip tests, and saliva collection. The exact purpose and effects of AEG-COVID are not specified in the provided information.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | A: EG-COVID |
|---|---|
| Sponsor | EyeGene Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
- Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants (PHASE1)
- Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19
- Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult (PHASE1, PHASE2)
- Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers (PHASE1, PHASE2)
- COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses
- IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A: EG-COVID CI brief — competitive landscape report
- A: EG-COVID updates RSS · CI watch RSS
- EyeGene Inc. portfolio CI
Frequently asked questions about A: EG-COVID
What is A: EG-COVID?
Who makes A: EG-COVID?
What development phase is A: EG-COVID in?
Related
- Manufacturer: EyeGene Inc. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing